Evidence map›Paper›PMID 39619605›Full record

ArticleJournal of hepatocellular carcinoma2024

Interventional Combined Microwave Ablation for Primary Neuroendocrine Carcinoma of the Liver Failing Systemic Chemotherapy: A Case Report.

Yang Fang, Xiuying Jin, Huiying Cui, Zhezhu Han, Qiang Xu, Songnan Zhang

Abstract readCase Reports
In one paragraph

Article in Journal of hepatocellular carcinoma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yang FangDepartment of Oncology, Yanbian University Hospital, Yanji, People's Republic of China.
Xiuying JinDepartment of Oncology, Yanbian University Hospital, Yanji, People's Republic of China.
Huiying CuiDepartment of Oncology, Yanbian University Hospital, Yanji, People's Republic of China.
Zhezhu HanDepartment of Oncology, Yanbian University Hospital, Yanji, People's Republic of China.
Qiang XuDepartment of Oncology, Yanbian University Hospital, Yanji, People's Republic of China.
Songnan ZhangDepartment of Oncology, Yanbian University Hospital, Yanji, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary hepatic Neuroendocrine carcinoma (PHNEC) is exceptionally rare, and when it cannot be surgically removed locally, systemic combination therapy is the preferred treatment. However, current treatments have shown limited effectiveness, and more effective approach remains a matter of debate. Case Presentation: We present a case involving a female patient diagnosed with non-surgically suitable PHNEC, confirmed through pathology. Following four cycles of standard first-line systemic chemotherapy, this intervention was prompted by imaging indicating suboptimal local lesion control, the patient underwent localized interventional and microwave ablation therapy. Subsequently, an evaluation based on mRECIST criteria revealed complete remission post-procedure. The disease sustained this remission status throughout the 14-month follow-up, with the administration of 14 cycles of immunocheckpoint inhibitor maintenance therapy, showing no signs of local recurrence or distant metastasis and devoid of any associated complications. Conclusion: This case introduces a novel therapeutic avenue for individuals who are ineligible for surgery and have not responded to systemic chemotherapy. The diagnosis and management of PHNEC are deliberated within the framework of this particular case.

Indexed as

interventionallarge cellliverneuroendocrine carcinomaprimary hepatic neuroendocrine carcinoma

Identifiers

PMID39619605
PMCPMC11608042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.